MedTrace Logo

Risk of Hepatitis B Reactivation in Patients With Prior HBV Exposure Undergoing Rituximab-containing Chemotherapy: A Prospective Study

NCT01502397 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2019-10-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether preemptive nucleoside analogue therapy or regular virologic monitoring is the preferred method in management patients with prior exposure to hepatitis B vius (HBV) and undergoing rituximab-containing chemotherapy.

Conditions

  • Exposure to Hepatitis B Virus

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Man-Fung Yuen, FRCP · The University of Hong Kong

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2015-12-31
Completion
2016-03-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01502397 on ClinicalTrials.gov